Invest NY: Health & Wellbeing Post author:admin Post published:February 4, 2021 Post category:News / Other News / Press Releases You Might Also Like Henrietta-Based Diffinity Genomics Acquired by Chiral Technologies January 19, 2016 Traverse Biotech announces a world-wide license agreement with Genmab to develop and commercialize a novel cancer bispecific antibody September 12, 2023 Excell Board Member Robert Genco remembered. March 13, 2019
Traverse Biotech announces a world-wide license agreement with Genmab to develop and commercialize a novel cancer bispecific antibody September 12, 2023